| Spectrum Pharma begins patient enrollment in phase 1 trial evaluating safety ... - pharmabiz.com |
|
|
pharmabiz.com Hyperphosphatemia in Stage 5 CKD, also known as end-stage renal disease (ESRD), can lead to significant bone disease (including pain and fractures), secondary hyperparathyroidism and cardiovascular disease, and is independently associated with |